FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average burden								
- 1	L	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Clancy Paul J</u>					2. Issuer Name and Ticker or Trading Symbol Xilio Therapeutics, Inc. [ XLO ]						(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last) (First) (Middle) C/O XILIO THERAPEUTICS, INC. 828 WINTER STREET, SUITE 300					3. Date of Earliest Transaction (Month/Day/Year) 10/26/2021								Officer (give title Other (specify below) below)				
(Street) WALTHAM MA 02451  (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date,			3. Transaction	4. Securi Dispose tr. 5)	of, or Ber ities Acquire d Of (D) (Inst	d (A) or r. 3, 4 and	5. Amount of 4 and Securities Beneficially Owned Followin Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
		-							uired, Dis , options,				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution [		Date, Transaction Code (Instr				6. Date Exerc Expiration D (Month/Day/	ate	of Securiti Underlying Derivative	Title and Amount Securities Iderlying Privative Security Istr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				Co	ode \	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Option (right to	\$5.51	10/26/2021			A		44,033		(1)	07/22/2030	Common Stock	44,033	\$0.00	44,033	D		
Stock Option (right to buy) Stock Option (right to	\$5.51 \$5.89	10/26/2021			A A		44,033 65,528		(1)	07/22/2030		44,033 65,528	\$0.00	44,033 65,528	D D		

- 1. On July 23, 2020, the reporting person was granted an option to purchase 44,033 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's initial public offering ("IPO"). The Company's IPO closed as of October 26, 2021. On October 26, 2021, 13,760 shares underlying the award vested and the remainder will vest in equal monthly installments until July 16,
- 2. On March 11, 2021, the reporting person was granted an option to purchase 65,528 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's IPO. The Company's IPO closed as of October 26, 2021. On October 26, 2021, 20,477 shares underlying the option vested and the remainder will vest in equal monthly installments until July 16, 2024.

/s/ Chris Frankenfield attorney-10/25/2021 in-fact for Paul Clancy

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.